Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

Mary Ellen Csuka MD
Professor
Department of Medicine
Division of Rheumatology

OFFICE ADDRESS:
The Hub for Collaborative Medicine
8701 Watertown Plank Road
Milwaukee, WI 53226

EDUCATION:
09/1968 - 06/1972 B.S., Fordham University, Bronx, NY
06/1974 - 06/1977 M.D., New York Medical College, Valhalla, NY

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
01/1977 - 06/1980 Resident, Department of Internal Medicine, The Hartford Hospital, Hartford, Connecticut 06115
1982 - 1985 Clinical Rheumatology Assistant to Dr. Daniel McCarty, Professor & Chairman, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226
09/1985 - 08/1986 Rheumatology Registrars to Professor Dame Carol M Black, FMedSci, West Middlesex University, West Middlesex University Hospital, Isleworth, Middlesex TW7 6AF
2005 - 2006 University of Wisconsin-Milwaukee, Faculty Leadership Development Program, UW-Medical College of Wisconsin, Certificate of Completion, Milwaukee, WI

FACULTY APPOINTMENTS:
07/1980 - 06/1982 Instructor of Medicine, Department of Medicine, Division of General Internal Medicine, Medical College of Wisconsin, Milwaukee, WI 53226
07/1982 - 06/1987 Assistant Professor, Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI 53226
07/1987 - 06/2006 Associate Professor, Department of Medicine, Division of Rheumatology, The Medical College of Wisconsin, Milwaukee, WI 53226
07/2006 - Present Professor, Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI 53226

ADMINISTRATIVE APPOINTMENTS:
1999 - Present Director, Rheumatology Inpatient Consultative, Medical College of Wisconsin, Milwaukee, WI
2001 - 2012 Founder and Director, Osteoporosis Clinic, Medical College of Wisconsin, Milwaukee, WI
2001 - 2005 Director, Rheumatology Clinic, Medical College of Wisconsin, Milwaukee, WI
2003 - Present Scleroderma Clinic, Scleroderma Foundation Research and Treatment Center, Froedtert and Medical College Clinics, 9200 W. Wisconsin Avenue, Milwaukee, WI 53226

HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS:
2004 - 2012 Epic Physician Council, Froedtert and Medical College Clinics, 9200 W. Wisconsin Ave., Milwaukee, WI 53226

HOSPITAL STAFF PRIVILEGES:
1979 - 1980 Emergency Room Physician, Emergency Room, Winsted Hospital, Winsted, CT 06098
1980 - 1996 Milwaukee County Medical Complex, 8700 W. Wisconsin Avenue, Milwaukee, WI 53226
1982 - Present Froedtert Memorial Lutheran Hospital, 9200 W. Wisconsin Avenue, Milwaukee, WI 53226
1988 - 2012 Zablocki Veterans Administration Medical Center, 5000 W. National Avenue, Milwaukee, WI 53295

SPECIALTY BOARDS AND CERTIFICATION:
Board Certified
Issue DateExpiration
National Board of Medical Examiners
1977
None
American Board of Internal Medicine
09/1980
None
ABIM - Rheumatology
11/1996
None
ABIM - Geriatric Medicine
2009
2019
   
Certificates
Issued By Issue DateExpiration
ACLS
AHA
1980
None
Rodnan Skin Score
SCOT
05/13/2005
None
Certified Clinical Densitometrist (CCD)
ISCD
07/29/2019
07/29/2024
CITI Refresher
MCW - CITI program
05/27/2020
05/27/2023
Basic CITI
CITI program
05/27/2020
05/27/2023
Human Research - Biomedical Research and Good Clinical Practices
MCW - CITI Program
05/28/2023
05/28/2026
Good Clinical Practice Course (US FDA focus) 2-GCP
MCW - CITI Program
08/17/2024
08/17/2027
Human Research - Learner Group 3 - 4 Refresher Course
MCW - CITI Program
08/17/2024
08/17/2027
    

Licensure
Number Issue DateExpiration
DEA
AC9388009
08/1978
08/31/2024
Wisconsin License
23008
07/11/1980
10/31/2025
    

AWARDS AND HONORS:
05/1972 - Present Magna Cum Laude, Kappa Gamma Pi
05/1973 - Present Phi Beta Kappa
1977 - Present Alpha Omega Alpha
1985 - Present Certification of Leadership Award - YWCA of Greater Milwaukee
1992 - Present Who's Who Registry of Rising Young Americans
1996 - Present Best Doctors in America®, Category; Rheumatology (elected by peers)
1998 - Present AMA Physician's Recognition Award
2004 - 2008 2010, 2014 - 2016 "Milwaukee's Top Doctors, " Category; Rheumatology, Milwaukee Magazine (elected by peers)
2004 - Present United Who's Who
2012 - Present Best Doctors in America®, Category; Geriatric Medicine (elected by peers)
07/20/2024 Doctor of the Year, National Scleroderma Foundation

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
Alpha Omega Alpha Medical Honor Society
American Association for the Advancement of Science
American College of Physicians (Fellow)
American College of Rheumatology (Fellow)
American Federation for Clinical Research
Scleroderma Clinical Trials Consortium
International Society for Clinical Densitometry
Society of Irish and American Rheumatologist
Wisconsin Bone Club
Pulmonary Hypertension Association Clinician and Researcher
International Bone and Mineral Society

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
10/2003 - 10/2006 Treasurer, ACR/ARHP Annual Meeting, Scleroderma Clinical Trials Consortium, Title: Moderator, Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s-Clinical Aspects and Therapeutics, III
08/2012 - 06/2020 Chairperson, Protocol: FHCRC 2533 – A Phase II Multi-Center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation with Post Transplant Maintenance for the Treatment of Systemic Sclerosis. Short Title: Scleroderma Treatment with Autologous Transplant (STAT) Study, Data and Safety Monitoring Board (DSMB)

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Active
Peer Review
Title:
Pulmonary Hypertension Registry of Scleroderma (PHROS)
Source:
SCTC supported by unrestricted grant – Actelion Pharmaceuticals U.S.
Role & Effort:
MCW Principal Investigator
Dates:
2004 - Present
  
Title:
Long-term Follow-Up of Participants in the Scleroderma: Cyclophosphamide or Transplantation (SCOT) Trial
Source:
Duke University
Role & Effort:
MCW Principal Investigator
Dates:
06/2018 - Present
  
Title:
SCTC SRCII Scleroderma Clinical Trial Consortium (SCTC) Working Group on Scleroderma Renal Crisis
Source:
None
Role & Effort:
MCW Principal Investigator
Dates:
04/2020 - Present
  
Non-Peer Review
Title:
KD025-209 A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Diffuse Cutaneous Systemic Sclerosis
Source:
Kadmon corporation
Role & Effort:
MCW Principal Investigator
Dates:
10/2020 - Present
  
Prior
Peer Review
Title:
Clinical Centers for the Clinical Trial and Observational Study of the
Source:
NIH
Role & Effort:
MCW Co-Investigator
Dates:
10/1994 - 10/1998
  
Title:
Study of Scleroderma Development of a Systemic Sclerosis Activity Index
Source:
Scleroderma Clinical Trials Consortium
Role & Effort:
MCW Co-Investigator
Dates:
1999 - 2000
  
Title:
Prospective Study of Treatment
Source:
Scleroderma Clinical Trials Consortium
Role & Effort:
MCW Principal Investigator
Dates:
1999 - 2002
  
Title:
Open Label Trial of Minocycline in the Treatment of Systemic
Source:
Scleroderma Clinical Trials Consortium
Role & Effort:
MCW Principal Investigator
Dates:
2000 - 2002
  
Title:
Safety of Estrogens in Systemic Lupus Erythematosus National
Source:
Johns Hopkins National Institutes of Health
Role & Effort:
MCW Co-Investigator
Dates:
2000 - 2003
  
Title:
Evaluation of the Usability of Computerized Intervention: Phase I-PDA Sigma Theta Tau, Delta Gamma Chapter
Role & Effort:
PI-MCW (Marquette University PI Polly Ryan, PhD)
Dates:
03/2002 - 03/2003
  
Title:
Evaluation of the Usability of Computerized Intervention: Phase II-Tailored Website
Source:
Sigma Theta Tau, Delta Gamma Chapter
Role & Effort:
PI-MCW (Marquette University PI Polly Ryan, PhD)
Dates:
03/2003 - 03/2004
  
Title:
CORRONA Data Collection Program
Source:
Consortium of Rheumatology Researchers of North America
Role & Effort:
MCW Principal Investigator
Dates:
2003 - 2018
  
Title:
Hsp90 Mediates eNOS and Vascular Function in SSc
Source:
NHLBI
Role & Effort:
Co-Investigator
Dates:
07/01/2004 - 06/30/2009
  
Title:
Apo A-1 Mimetics, HDL, Dysfunction in Scleroderma
Source:
National Scleroderma Foundation
Role & Effort:
Consultant
Dates:
01/01/2005 - 12/31/2008
  
Title:
A Randomized, Open-Label, Phase II/III Multi-Center Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation with Auto-CD34+HPC versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis.
Source:
NIH Contract NO1-AI-05419 SCOT Trial
Role & Effort:
MCW – PI (17% effort)
Dates:
03/03/2005 - 09/09/2012
  
Title:
Left ventricular diastolic dysfunction in patients with collagen vascular
Source:
Not funded
Role & Effort:
Co-Investigator
Dates:
08/31/2007 - 08/30/2008
  
Title:
Effectiveness of Tailored Intervention for Osteoporosis Prevention: Medical College of Wisconsin. GCRC Grant MO1-RR00058 Support includes data collection, intervention delivery, technology assistance, nutritionist, and statistical consultation.
Source:
Medical College of Wisconsin
Role & Effort:
Co-Investigator with Polly Ryan
Dates:
2007 - 2009
  
Title:
Effectiveness of Tailored Intervention for Osteoporosis Prevention
Source:
NIH
Role & Effort:
Co-Investigator
Dates:
2007 - 2008
  
Title:
Bone Mineral Density in Multiple Sclerosis: Endogenous and Exogenous Factors
Source:
National Multiple Sclerosis Society-Pilot Research Project Marquette IRB Ref #: HR-1605
Role & Effort:
Co-Investigator
Dates:
05/01/2008 - 04/30/2009
  
Title:
Tailored Computerized Intervention for Behavior Change
Source:
NIH
Role & Effort:
Co-Investigator
Dates:
2008 - 2009
  
Title:
Role of Microfibril and Connective Tissue Function in Endothelial Mesenchymal Transition in Scleroderma
Source:
Clinical and Translational Science Institute
Dates:
04/2010 - 06/2014
  
Non-Peer Review
Title:
Oral Iloprost for the Treatment of Raynaud’s Phenomenon Second Systemic Sclerosis
Source:
Berlex Laboratories
Role & Effort:
MCW Principal Investigator
Dates:
12/1995 - 11/1996
Direct Funds:
$69,150
  
Title:
A Phase I Study of Subcutaneous Continuous Infusion of Recombinant Human Relaxin Manufactured by a Single Chain Process in Patients with Systemic Sclerosis with Diffuse Scleroderma
Source:
Connectics Corporation
Role & Effort:
Principal Investigator
Dates:
02/1996 - 01/1997
Direct Funds:
$31,256
  
Title:
A Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Repeated Doses of LJP 394 in Patients with Systemic Lupus
Source:
Erythematosus La Jolla Pharmaceutical
Role & Effort:
MCW Co-Investigator
Dates:
1996 - 1997
  
Title:
Placebo Controlled Comparison of the Efficacy and Safety of Etodolac Extended Release with Nabumetone in Patients with Active Rheumatoid Arthritis Followed by a Long-Term Open Label Extension
Source:
Wyeth Research
Role & Effort:
MCW Co-Investigator
Dates:
1996 - 1998
  
Title:
A Phase II/III Placebo –Controlled Safety and Efficacy Study of Recombinant Human Relaxin Therapy in Subjects with Systemic Sclerosis with Diffuse Scleroderma
Source:
Connetics Corporation
Role & Effort:
MCW Principal Investigator
Dates:
1999 - 2001
Direct Funds:
$112,703
  
Title:
An Open-Label Study of Safety of Subcutaneous Continuous Infusion of Recombinant Human Relaxin for 52 Weeks in Subjects with Systemic Sclerosis
Source:
Connetics Corporation
Dates:
1999 - 2001
Direct Funds:
$16,158
  
Title:
A Multicenter Blinded, Randomized, Placebo-controlled to study the Ability of IL-1ra (anakinra) to Retard Joint Destruction And Evaluate the Long Term Safety of IL-1ra, in Subjects with Rheumatoid Arthritis
Source:
Amgen
Role & Effort:
MCW Co-Investigator
Dates:
1999 - 2003
  
Title:
A Randomized Double Blind Placebo-controlled Multi-Center Safety and Efficacy Trial of LJP394 in Systemic Lupus Erythematosus (SLE) Patients with History of Renal Disease.
Source:
LaJolla Pharmaceutical Co
Dates:
2000 - 2003
  
Title:
Fracture Incidence Reduction and Safety of TSE – 424 (Bazedoxifene Acetate) Compared to Placebo and Raloxifene in Osteoporotic Postmenopausal Women
Source:
Wyeth Ayerst Pharmaceutical
Role & Effort:
MCW Co-Investigator
Dates:
2001 - 2011
  
Title:
A Multicenter, Blinded, Randomized, Placebo-controlled Study of OPC-28326 in Subjects with Raynaud’s Phenomenon
Source:
Otsuka Maryland Research
Dates:
2001 - 2002
Direct Funds:
$32,800
  
Title:
An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial with a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women with Postmenopausal Osteoporosis.
Source:
NPS Allelix Corporation
Dates:
01/11/2002 - 02/02/2005
  
Title:
A Randomized, Double-Blind, Multicenter Study to evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 50 mg t.i.d. in Patients with Osteoarthritis, EDGE
Source:
Merck & Co
Role & Effort:
MCW Principal Investigator
Dates:
2002 - 2004
Direct Funds:
$10,428
  
Title:
A 13-week, Multicenter, International, Randomized Double-blind, Placebo controlled Parallel Group Study of 2 doses of COX189 (200 mg and 400 mg q d.) in patients with Rheumatoid Arthritis using Naproxen (500 mg b.i.d.) as comparator
Source:
Novartis Pharmaceutical
Role & Effort:
MCW Co-Investigator
Dates:
2002 - 2003
  
Title:
An Open-Label, Multicenter, Long-Term Continuation, Safety Trial of LJP 394 in Systemic Lupus Erythematosus (SLE) Patients With a History of Renal Disease
Source:
LaJolla Pharmaceutical Co
Role & Effort:
MCW Co-Investigator
Dates:
2002 - 2003
  
Title:
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study To Assess the Effect of Bosentan on Healing and Prevention of Ischemic Digital Ulcers in Patients with Systemic Sclerosis (RAPIDS- 2)
Source:
Actelion Pharmaceuticals U.S.
Dates:
2003 - 2004
  
Title:
An Epidemiological Study of the Point Prevalence of Undiagnosed PAH in Patients with Connective Tissue Disease (UNCOVER)
Source:
Actelion Pharmaceuticals U.S.
Role & Effort:
MCW Principal Investigator
Dates:
2003 - 2004
Direct Funds:
$28,000
  
Title:
A Multicenter, Randomized, Double-Blind, Placebo and Active- Controlled, Phase 2, Parallel Group, Dose-Range Finding Study to Assess the Safety and Efficacy of GW406381 Administered for 42 days to Subjects with Rheumatoid Arthritis
Source:
GlaxoSmith Kline
Role & Effort:
MCW Co-Investigator
Dates:
2003 - 2004
  
Title:
A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Dose- Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of Lymphostat-B Antibody in Subjects with Rheumatoid Arthritis.
Source:
Human Genome Sciences
Role & Effort:
MCW Co-Investigator
Dates:
2003 - 2006
  
Title:
A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Dose- Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of LymphoStat-B Antibody (Monoclonal Anti-BLyS Antibody) in Subjects with Systemic Lupus Erythematosus
Source:
Human Genome Sciences
Role & Effort:
MCW Co-Investigator
Dates:
2004 - 2006
  
Title:
Clinical Screening Protocol to Characterize the Clinical Status of Scleroderma Patients for Potential Inclusion in a Clinical Trial.
Source:
Genzyme Corporation
Role & Effort:
MCW Principal Investigator
Dates:
2004 - 2005
Direct Funds:
$3,200
  
Title:
A Double-Blind, Parallel, Placebo-Controlled Randomized Study To Evaluate the Efficacy and Safety of 3 Different Oral Dose Levels (1, 2, and 4mg) of CCI-779 in Subjects with Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy.
Source:
Wyeth Ayerst Pharmaceutical
Role & Effort:
MCW Co-Investigator
Dates:
2004 - 2005
  
Title:
Phase III “In-Life” Study of a Topical Gel Formulation of Nitroglycerin, MQX-503 and Matching Placebo Gel in the Treatment and Prevention of Raynaud’s Phenomenon.
Source:
MediQuest Therapeutics, Inc
Role & Effort:
MCW Principal Investigator
Dates:
03/2006 - 10/2006
  
Title:
Long Term Bosentan Open Label Extension of the RAPIDS-2 Study in Systemic Sclerosis Patients with Ischemic Digital Ulcers.
Source:
Actelion Pharmaceuticals U.S.
Role & Effort:
MCW Principal Investigator
Dates:
05/2006 - 06/2009
  
Title:
A randomized, double-blinded, placebo controlled, multiple-dose Multi-center study to assess safety, tolerability, pharmacokinetics and Pharmacodynamics of intravenous doses of QAX576 in patients with Pulmonary fibrosis secondary to systemic sclerosis. Protocol No: CQAX576A2201
Source:
Novartis
Role & Effort:
MCW Principle Investigator
Dates:
10/01/2007 - 07/31/2009
  
Title:
Phase III Open Label Study of a Topical Gel Formulation of Nitroglycerin, MQX-503 in the Treatment and Prevention of Raynaud’s Phenomenon.
Source:
MediQuest Therapeutics, Inc.
Role & Effort:
MCW Principal Investigator
Dates:
01/2008 - 07/2009
Direct Funds:
$6,000
  
Title:
DETECT. AC-052-510. A two-stage prospective observational cohort study in scleroderma patients to evaluate screening tests and the incidence of pulmonary arterial hypertension and pulmonary hypertension. Early, simple and reliable DETECTion of PAH in SSC
Source:
Actelion
Role & Effort:
MCW Principle Investigator
Dates:
03/2009 - 01/2012
Direct Funds:
$360,000
  
Title:
A Study of a Topical Formulation of Nitroglycerin, Vascana® (MQX- 503), and Matching Vehicle in the Treatment and Prevention of Symptoms Associated with Raynaud’s Phenomenon Clinical Study Protocol Number 09-001
Source:
Mediquest
Role & Effort:
MCW Principle Investigator
Dates:
07/2009 - 09/2010
  
Title:
DISTOL-1: Digital Ischemic Lesions in Scleroderma Treated with Oral Treprostinil Diethanolamine: A Randomized, double-blind, placebo- controlled, multicenter study
Source:
United Therapeutics
Role & Effort:
MCW Principal Investigator
Dates:
01/2010 - 10/10/2011
Direct Funds:
$20,000 (20000 Per Patient)
  
Title:
DISTOL EXT: Digital Ischemic Lesions in Scleroderma Treated with Oral Treprostinil Diethanolamine: An open-label multicenter extension study. Protocol TDE-DU-202
Source:
United Therapeutics
Role & Effort:
MCW Principal Investigaor
Dates:
10/2011 - 11/2012
  
Title:
HGS LBSL99 160-05 A Multi-Center, Open-Label, Continuation Trial of LymphoStat-B Antibody (Monoclonal Anti-BLyS Antibody) in Subjects with Systemic Lupus Erythematosus (SLE) Who Completed the Phase 2 Protocol LBSL02
Source:
Human Genome Sciences
Role & Effort:
Principal Investigator
Dates:
08/2012 - 06/2016
  
Title:
A Phase 2, Proof-of-Concept, Multicenter, Randomized, Double-Blind, Placebo-Controlled study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of pomalidomide (CC-4047) in subjects with systemic sclerosis with interstitial lung disease
Source:
Celgene Corporation
Role & Effort:
Principal Investigator
Dates:
09/2012 - 11/2012
Direct Funds:
$26,000
  
Title:
DISTOL 3: A Retrospective Look at the Recurrence of Digital Ulcers after Discontinuation of Oral Treprostinil
Role & Effort:
MCW Principal Investigator
Dates:
04/2013 - 04/2014
  
Title:
VAS-014-001: A Double-blinded Crossover Study of Topical Formulation of Nitroglycerine, Vascana, versus Matching Vehicle in the Subjective and Physiologic Responses to Controlled Cold Challenge in Subjects with Raynaud Phenomenon (RP) Secondary to Connective Tissue Disease
Source:
Quintiles, Inc.
Role & Effort:
MCW Principal Investigator
Dates:
05/2016 - 02/2017
  
Title:
BI Trial No.: 199.213 A double blind, randomized, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with "Systemic Sclerosis associated Interstital Lung Disease (SSc-ILD).
Source:
Boehringer Ingelheim
Role & Effort:
MCW Principal Investigator
Dates:
01/2017 - 04/2019
  
Title:
JBT101-SSc-002 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy an Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Source:
Corbus Pharmaceuticals
Role & Effort:
MCW Principal Investigator
Dates:
09/2018 - 11/2021
Direct Funds:
$12,350
  
Title:
Aurora ES-301 A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes
Source:
Medpace
Role & Effort:
MCW Principal Investigator
Dates:
12/2019 - 09/2021
  

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
International
Update on Fibromyalgia, Royal Free Hospital, London, U.K., 07/1996
 
Regional
Rheumatologic Diagnosis, Intensive Training Program for the Wisconsin Geriatric Education Center, Chippewa Falls, WI, 06/03/1998
Cox –2 Sparing Drugs and Treatment of Arthritis, Annual Staff Meeting, Northwest General Hospital, Milwaukee, WI, 06/1999
Osteoporosis, Women’s Health for Primary Care Physicians, Medical College of Wisconsin OB-GYN, Milwaukee, WI, 08/10/1999
New Therapies for Rheumatoid Arthritis: Role of TNFa Antagonists, 12th Annual MCW Primary Care Conference, Egg Harbor, WI, 10/09/1999
Cox-2 Specific Inhibitors in the Treatment of Arthritis, Family Practice Clinical Conference, St. Francis Hospital, Milwaukee, WI, 11/10/1999
Osteoporosis 2000: Who, When & How to Treat,, Symposium Planning Committee, Wyndham Milwaukee Center Hotel, Milwaukee, WI, 11/18/2000
Painting a Brighter Picture for PAH Patients, PAH Symposium - Panel Discussant, Milwaukee, WI, 04/2002
Rheumatology and Pharmacology: Conservative Management of the RA Patient, Invited lectures for Current Trends for Treatment of The Arthritic Upper Extremity presented by The University of Wisconsin-Milwaukee, College of Health Sciences and the American Society of Hand Therapists, 04/11/2003
Understanding Other Forms of Arthritis and Related Conditions, Invited lectures for Current Trends for Treatment of The Arthritic Upper Extremity presented by The University of Wisconsin-Milwaukee, College of Health Sciences and the American Society of Hand Therapists, Milwaukee, WI, 04/11/2003
Duration and Safety of Immunomodulator Therapy in IBD: A Rheumatologist's Perspective, Presented at Difficult Decisions in IBD sponsored by CCFA Wisconsin Chapter, Wisconsin Dells, WI, WI, 03/27/2004
Physical Therapy and Occupational Therapy in Osteoporosis, Wisconsin's Osteoporosis Symposium, Milwaukee, WI, 06/25/2004
Pulmonary Hypertension and Connective Tissue Disease: Shedding Light on Pulmonary Arterial Hypertension, Sponsored by the Pulmonary Hypertension Association, Chicago, IL, 10/08/2005
Osteoporosis in Rheumatologic Practice, The Pfister Hotel Wisconsin Osteoporosis Symposium, Milwaukee, WI, 06/16/2006
Clinical Densitometry and Osteoporosis, 2007 Annual Spring Meeting, Transitioning from Nuclear Medicine to Molecular Imaging: Are We Really Ready? Central Chapter Society of Nuclear Medicine, Chicago, IL, 03/10/2007
Scleroderma 101: Understanding the Basics of Systemic Sclerosis, Rheumatology Nurses' Society 2024 Winter Symposium, Virtual, 01/11/2025
Scleroderma, 2025 Wisconsin Rheumatology Association Annual Meeting, Kohler, WI, 03/21/2025
"Medical Management of Rheumatoid Arthritis of the Cervical Spine, " 10th Annual MCW Spine Symposium, Children's Hospital, Milwaukee
 
Local
Antibodies and Scleroderma, Scleroderma Lunch & Learn Webinar, West Allis-West Milwaukee Recreation Department- 2450 S. 68th Street - West Allis, WI 53219, 03/29/2025
 

COMMITTEE SERVICE:
Medical College of Wisconsin
1982 - 1985 The Impaired Residents Committee, Medical College Affiliated Hospitals Program, Medical College of Wisconsin
1984 - 1985 Ad Hoc Committee, Departmental Annual Report, Medical College of Wisconsin
1986 - 1989 House Staff Assistance Committee, Medical College Affiliated Hospitals Program, Medical College of Wisconsin
1991 - 1992 Dean's Task Force on PM&R, Medical College of Wisconsin
2001 - 2002 Academic Standing Committee (elected by peers), Medical College of Wisconsin
2002 - 2009 Review Committee, Sabbatical Leave and Faculty Vitality Awards, Medical College of Wisconsin
 
Hospital
1987 - 1998 Joint Credentials Committee, Froedtert Memorial Lutheran Hospital/Milwaukee County Medical Complex, Milwaukee, WI
1992 - 1993 Patient Education Committees, Froedtert Memorial Lutheran Hospital
 

MCW TEACHING ACTIVITIES:
Medical Student Education
1981 - 1982 Sophomore Preceptor, Introduction to Clinical Medicine
1982 - 1987 Instructor, Junior Rounds
1991 “Inflammation and Biochemistry”, Clinical Correlation Lecture, Department of Biochemistry
1995 Physical Diagnosis
09/2013 2 Sessions; Pathologic History & Exam Findings, Musculoskeletal Skills Workshop for Bench-to-Bedside
04/03/2014 Discussant, Clinical Pathologic Conference
09/2015 Musculoskeletal Skills Workshop for Bench-to-Bedside 2 Sessions; Pathologic History & Exam Findings
09/2016 Musculoskeletal Skills Workshop for Bench-to-Bedside 2 Sessions; Pathologic History & Exam Findings
 
Resident and Fellow Education
1989 Arthritis of the Foot, Ortho-Rheum Conference
01/1992 Helpful Laboratory Tests in Rheumatology, Ortho-Rheum Conference
09/1992 "Osteoporosis, " Ortho-Rheum Conference, Children's Hospital
11/1992 Geriatric Rheumatology Core Curriculum lecture
12/1992 Neurologic complications of Rheumatic Diseases, Department of Neurology
10/1995 “Avascular necrosis,” Rheum Conference
08/1998 "NSAIDS, " Ortho-Rheum Conference
11/1998 "Rheumatoid Arthritis, " Internal Medicine Resident Lecture, FMLH/VAMC
05/1999 "Osteoporosis, " Ortho-Rheum Conference, Children's Hospital
06/1999 "Cox -2 Sparing Drugs and Treatment of Arthritis, " Family Practice
12/02/1999 "Update on Scleroderma, " Internal Medicine Resident Lecture, FMLH/VAMC
12/16/1999 "Update on Scleroderma, " Internal Medicine Resident Lecture, FMLH/VAMC
01/03/2001 NSAIDS, " Ortho-Rheum Conference
04/2001 "Management of Fibromyalgia, " Internal Medicine Resident Lecture, FMLH/VAMC
09/2001 "Fibromyalgia, " Neurology Training Program - Clinical Lecture Series, Medical College of Wisconsin
12/2001 Scleroderma, " Internal Medicine Resident Lecture, FMLH/MCW
01/2002 "Osteoporosis, " Ortho-Rheum Conference, Children's Hospital
04/2004 "Osteoporosis, " Ortho-Rheum Conference, Children's Hospital
05/2005 Scleroderma, " Internal Medicine Resident Lecture, FMLH/MCW
08/2005 "Osteoporosis, " Ortho-Rheum Conference, Children's Hospital
11/02/2006 “Rheumatologic Disease and the Paranasal sinuses and related structures” PGY 1, Core Curriculum for ENT residents
02/21/2007 "Overview of Pathogenesis and Treatment of Rheumatoid Arthritis, " MCW- PM&R Core Curriculum, FMLH
03/07/2007 Overview of Pathogenesis and Treatment of Rheumatoid Arthritis Core Curriculum Hand Surgery
04/20/2007 "Soft Tissue Rheumatism, " Internal Medicine Resident conference,
05/07/2007 "Soft Tissue Rheumatism, " Internal Medicine Resident conference,
05/30/2007 "Osteoporosis-Basic Science, " Core Curriculum for Orthopedic Residents, Children's Hospital of WI
07/18/2007 Rheumatoid Arthritis, Academic Half Day: PGY 2+
07/25/2007 Rheumatoid Arthritis, Academic Half Day: PGY 1
09/21/2007 Treatment of Psoriatic Arthritis, Dermatology Resident Core Curriculum
04/09/2008 Overview of Pathogenesis and Treatment of Rheumatoid Arthritis Core Curriculum Hand Surgery
07/23/2008 Rheumatoid Arthritis, Academic Half Day: PGY 1
07/30/2008 Scleroderma, Academic Half Day: PGY 2+
09/04/2008 “Rheumatologic Disease and the Paranasal sinuses and related structures” PGY 1, Core Curriculum for ENT residents
07/08/2009 “Rheumatologic Disease and the Paranasal sinuses and related structures” PGY 1, Core Curriculum for ENT residents
07/08/2009 ANCA related Vasculitis. PGY 2+
08/05/2009 Osteoporosis, Academic Half Day: PGY 1
02/17/2010 Overview of Pathogenesis and Treatment of Rheumatoid Arthritis Core Curriculum Hand Surgery
07/14/2010 Scleroderma, Academic Half Day: PGY 2+
09/30/2010 “Rheumatologic Disease and the Paranasal sinuses and related structures” PGY 1, Core Curriculum for ENT residents
07/21/2013 RA diagnosis and Treatment, PG-1 Academic Half Day
07/21/2013 Soft Tissue Rheumatism, Fibromyalgia, Academic Half Day
07/24/2013 Scleroderma: PG2-3 Academic Half Day
07/29/2015 Scleroderma: PG-1 Academic Half Day
 
Continuing Medical Education
02/1994 "Geriatric Rheumatology", Wisconsin Board Review Course and
03/1996 "Geriatric Rheumatology, " Wisconsin Board Review Course and
03/1996 "Fibromyalgia, " Medical Grand Rounds, St. Mary's Hospital,
05/01/1996 "Management of Fibromyalgia, " MCW Primary Care Update, Traverse City, MI
02/1997 Osteoporosis Management, " PM&R Grand Rounds,
04/1998 "Temporal Arthritis, " Medicine Grand Rounds, Medical
03/1999 "Rheumatoid Arthritis, " Medical Grand Rounds, Kenosha Hospital
03/1999 "Cox-2 Specific Inhibitors, " Medical Grand Rounds, St.
04/1999 "New Treatments of Rheumatoid Arthritis, " Medical Grand Rounds, Munson Medical Center, Traverse City, MI
07/1999 "Scleroderma and Acute Renal Disease, " Medical Grand Rounds, Medical College of Wisconsin, Milwaukee College of Wisconsin
10/1999 "New Directions in the Management of Arthritis Pain, "
12/1999 "Cox-2 Specific Inhibitors: A New Era in Arthritis Treatment, " CME Dinner Meeting, Cincinnati, OH
02/2000 "Treatment of Steroid Induced Osteoporosis, " CME dinner meeting, Milwaukee, WI
09/2000 "Geriatric Rheumatology, " Wisconsin Board Review Course and
03/2001 "Osteoporosis: Evaluation and Treatment, " DO Annual Dinner, Milwaukee, WI
09/2002 "Geriatric Rheumatology, " Wisconsin Board Review Course and
09/2002 "Fibromyalgia, " Columbia-St. Mary's Fall Clinic, Milwaukee, WI
10/2002 "New Developments in the Diagnosis and Treatment of Osteoporosis, " Grand Rounds, St. Elizabeth Hospital, Appleton, WI
11/2003 "Current Recommendations in the Prevention and Treatment of
05/2004 "Osteoporosis: An Overview of Diagnosis, Prevention and Treatment, " All Saints Healthcare Grand Rounds, St. Mary's Medical Center, Racine, WI
10/2004 "Geriatric Rheumatology, " Wisconsin Board Review Course in Geriatric Medicine, Lake Geneva, WI
05/2006 "Osteoporosis, " Presented by invitation of Dean Dunn at the MCW Alumni Clinic Day, Milwaukee, WI
09/2006 "Geriatric Rheumatology, " Wisconsin Review Board Review Course in Geriatric Medicine, Waukesha, WI
12/2006 "Overview of Systemic Sclerosis and the SCOT Tria, " Medical Grand Rounds, St. John's Hospital, University of Oklahoma, Tulsa, OK
04/09/2008 "Osteoporosis-What's New, Management of Pain, " Co-presented with Dr. Sean Tutton, Intervention Radiologist, Grand Rounds Columbia Hospital, Milwaukee, WI
04/22/2008 "Osteoporosis-What's New, Management of Pain, " Co presented with Dr. Sean Tutton, Intervention Radiologist, Grand Rounds Columbia Hospital, Milwaukee, WI
05/01/2008 "Scleroderma- Advances in Treatment and Etiology, " NE Rheumatology, Appleton, WI
09/25/2008 "Geriatric Rheumatology, " Wisconsin Board Review Course in Geriatric Medicine, The Abbey, Fontina, WI
03/26/2010 "Systemic Scleroderma, A complex disease affecting real people, " Grand Rounds, Dept of Medicine, Helfaer Auditorium, FMLH - Milwaukee, WI
09/10/2013 Rheumatic Disease, Wisconsin Board Review Course in Geriatric Medicine, Grand Geneva, Lake Geneva WI
 
Community/Lay Public
02/1981 Health and Safety Issues for Hospital and Health Workers,” Women's Work, Women's Health: Moderator, A conference on health and safety for Woman. Milwaukee, WI
02/1984 “Medical Emergencies Common Illnesses and Injuries,” Participated as group leader in Health Activation Series at MCMC, Milwaukee, WI
03/1987 “Medical Aspects of Substance Abuse,” AFSME District Council 48 Conference, Milwaukee, WI
1987 - 1995 Medical Volunteer, St. Francis Meal Program Clinic, Milwaukee, WI
09/1989 “Rheumatologic Conditions Affecting Productivity,” Moderator Central State Occupational Medical Association Fall Seminar, Milwaukee, WI
04/1992 “Overview of Rheumatology, Medication, Treatments, Etc.,” Wisconsin Association of Life and Health Underwriters, Milwaukee, WI
07/1992 “Therapy and Treatment of Arthritis,” Minority Premedical Apprenticeship Program Medical College of Wisconsin, Milwaukee, WI
06/1993 “Overview of Arthritis,” Medical Social Services, Milwaukee County Hospital, Milwaukee, WI
11/1995 “Overview of Lupus,” Lupus Society of Wisconsin, Milwaukee, WI
1995 - 2007 Member, ESYCM Interparish Commission, Milwaukee, WI
02/1997 “Osteoporosis,” Federation of Nurse Retirees, Local 5001, Milwaukee, WI
11/1997 “Osteoporosis,” Community Education Froedtert Hospital, Milwaukee, WI
06/1999 “Benefits and Limitations of Current Therapies for Treatment of Osteoarthritis,” Patient Education Lecture, Oshkosh, WI
05/2001 “Osteoporosis: Healthy Aging Series,” Waukesha Area Technical College, Waukesha, WI
10/2002 “New Developments in Treatments of Osteoporosis,” Patient Education Lecture, Park Plaza Valley Inn, Neenah, WI
04/01/2004 “Bone Health,” Community Education Lecture sponsored by Froedtert and Medical College, Milwaukee, WI
10/08/2005 “Scleroderma and PAH: An Educational Update; Shedding Light on Pulmonary Arterial Hypertension,” Scleroderma Foundation Support Group sponsored by the Pulmonary, Hypertension Association, Holiday Inn Chicago City Center, Chicago Lupus Foundation, Milwaukee Chapter, IL
10/08/2005 “Osteoporosis and the Lupus Patient,” Lupus Foundation Milwaukee Chapter, Helfaer Auditorium, FMLH, Milwaukee, WI
09/30/2009 “Osteoporosis Update and Treatment of Bone Pain,” Community Education Lecture sponsored by Froedtert and Medical College, presented with Dr. Sean Tutton, Community Center, FMLH, Milwaukee, WI
 

EXTRAMURAL TEACHING:
Medical Student Education
1982 - Present Medical College of Wisconsin Affiliated Hospitals, Medical Ward Staffing
1987 - Present Froedtert and Medical College Rheumatology Clinic, Staff
2000 - Present Froedtert and Medical College Osteoporosis Clinic, Staff
 
Resident and Fellow Education
1980 - 1982 Milwaukee County Medical Complex, General Medicine Staff for Residents, General Internal Medicine Clinic
1982 - 1988 General Internal Medicine Clinic, Milwaukee County Medical Complex, General Medicine Staff for Residents
07/1992 St. Michael's Hospital, Milwaukee, WI, NSAID's-Indications/Complications,amily Practice Resident Lecture
03/1993 Milwaukee County Medical Complex, "Rheumatoid Arthritis” Internal Medicine Resident Lecture
04/1993 Milwaukee County Medical Complex, “Spondyloarthropathies,” Internal Medicine Resident Lecture
02/1994 Medical College of Wisconsin Pain Clinic, FMLH, “Fibromyalgia”
 
Continuing Medical Education
1995 Woods VA Hospital, Update on Inflammatory Myopathies,” Medical Grand Rounds
 


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Sullivan D, Csuka ME, Blanchard B. Erythromycin ethylsuccinate hepatotoxicity. JAMA. 1980 Mar 14;243(10):1074.
2. Csuka, M: McCarty, DJ. A Simple Measurement of Lower Extremity Muscle Strength. American Journal of Medicine 78:77-81, 1985 Jan;78(1):77-81 PMID: 3966492 01/01/1985.
3. Hansen, RM; Csuka, ME; McCarty, DJ. Gold Induced Aplastic Anemia. A Complete Response to Corticosteroids, Plasmapheresis and N-Acetylcysteine Infusion. The Journal of Rheumatology 1985 Aug; 12(4):794-7 PMID: 4057204 08/01/1985.
4. Csuka, M; Carrera, GF; McCarty, DJ. Treatment of Intractable Rheumatoid Arthritis with Combined Cyclophosphamide, Azathioprine, and Hydroxychloroquine: A Follow-Up Study. JAMA 1986 May 02;255(17):2315-9 PMID 3959321 05/02/1986
5. Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine, and hydroxychloroquine: A Follow-Up Study. Csuka M; Carrera GF; McCarty DJ. JAMA 1986 May 02;255(17):2315-9 PMID 3959321 05/02/1986.
6. Csuka, M; Brewer, B; Lynch, KL; McCarty, DJ. Osteonecrosis, Fractures, and Protrusion Acetabula Secondary to X-irradiation Therapy for Prostatic Carcinoma. The Journal of Rheumatology 1987 Feb;14(1):165-70 PMID: 3106631 02/01/1987.
7. McHugh, NJ; Csuka, M; Watson, H; Belcher, G; Amadi, A; Ring, EFJ; Black, CM; Maddison, PJ. Infusion of Iloprost, a Prostacyclin Analogue for Treatment of Raynaud's Phenomenon in Systemic Sclerosis. Ann Rheum Dis 1988 Jan;47(1):43-7 PMID: 2449871 01/01/1988.
8. Csuka, ME, McCarty, DJ. Aspirin and the treatment of rheumatoid arthritis. Rheumatic Diseases Clinic of North American 1989 Aug;15(3):439-54 PMID: 2672131 08/01/1989.
9. May, GD; Black, CM; Olsen, NJ; Csuka, ME, Tanner, BS; Belling, L; Porter, JA; Wilkinson, GR; Branch, RA. Scleroderma is Associated with Difference in Individual Routes of Drug Metabolism: A Study with Dapsone, Debrisoquine and Mephenytoin. Clin Pharm and Therapeutics 1990 Sep;48(3):286-95 PMID: 2401127 09/01/1990.
10. Derfus, BA; Csuka, ME; Carrera, GF; Hanson, GA; Smith, RE. Bone Remodeling After Growth Factor and Cyclosporine A Therapy for Aplastic Anemia. The Journal of Rheumatology 1991 May;18(5):738-42 PMID: 1865422 05/01/1991.
11. Black, C; May, G; Csuka, ME; Lupoli, S; Wilkinson, GR; Branch, RA. Activity of Oxidative Routes of Metabolism of Debrisoquine, Mephenytoin and Dapsone is Unrelated to Pathogenesis of Vinyl Chloride-induced Disease. Clinical Pharmacol Ther 1992 Dec;52(6):659-67 PMID: 1458774 12/01/1992.
12. McCarty, DJ; Csuka, ME; McCarthy, G; Trotter, D. Treatment of Pain Due to Fibromyalgia With Topical Capsaicin: A Pilot Study. Seminars in Arthritis and Rheumatism 23:41-47, 1994.
13. Taylor, ML; Trotter, DR; Csuka, ME. The Prevalence of Physical-Sexual Abuse in Women Diagnosed with Primary Fibromyalgia. Arthritis Rheum 1995 Feb;38(2):229-34 PMID: 7848313 02/01/1995.
14. Csuka, ME; Hanson, GA. Resolution of Soft Tissue Sarcoma in a Patient with Rheumatoid Arthritis after Discontinuation of Azathioprine. Archives of Internal Medicine 1996 Jul 22;156(14):1573-6 PMID: 8687266 07/22/1996.
15. Lorenzo, JP; Csuka, ME; Derfus, BA; Gotoff, RA; McCarthy, GM. Concurrent Gout and Mycobacterium Tuberculosis Arthritis. The Journal of Rheumatol 1997 Jan;24(1): 184-6 PMID: 9002033 01/01/1997.
16. Wigley, FM; Korn, JH; Csuka, ME; Medsger, TA, Jr; Rothfield, NF; Ellman, M; Martin, R, Collier; DH, Weinstein, A; Furst, DE; Jimenez, SA; Mayes, MD; Merkel, PA; Gruber, B; Kaufman, L; Varga, J; Bell, P; Kern, J; Marrott, P; White, B; Simms, RW; Phillips, AC; Seibold, JR. Oral Iloprost Treatment in Patients with Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Placebo-Controlled, Double-Blind Study. Arthris Rheum 1998 Apr;41(4):670-7 PMID: 9550476 04/29/1998.
17. Seibold, JR; Korn, JH; Simms, R; Clements, PJ; Moreland, LW; Mayes, MD; Furst, DE; Rothfield, N; Steen, V; Weisman, M; Collier, D; Wigley, FM; Merkel, PA; Csuka, ME; Hsu, V; Rocco, S; Erikson, M; Hannigan, J; Harkonen, WS; Sanders, ME. Recombinant Human Relaxin in the Treatment of Scleroderma: A Randomized, Double-Blind, Placebo-Controlled Trial. Ann Intern Med 2000 Jun 06;132(11):871-9 PMID: 10836913 06/03/2000.
18. Merkel, PA; Herlyn, K; Martin, RW; Anderson, JJ; Mayes, MD; Bell, P; Korn, JH; Simms, RW; Csuka, ME; Medsger, TA, Jr; Rothfield, NF; Ellman, MH; Collier, DH; Weinstein, A; Furst, DE; Jimenez, SA; White, B; Seibold, JR; Wigley, FM. Measuring Disease Activity and Functional Status in Patients with Scleroderma and Raynaud's Phenomenon. Arthritis Rheum 2002 Sep;46(9):2410-20 PMID: 12355489 10/02/2002.
19. Prajapati, DN; Knox, JF; Emmons, J; Saeian, K; Csuka, ME; Binion, DG. Leflunomide Treatment of Crohn's Disease Patients Intolerant to Standard Immunomodulator Therapy. J Clin Gastroenterol 2003 Aug;36(2):125-8 PMID: 12869881 Scopus ID: 2-s2.0-0038115119 07/19/2003.
20. Mayes, MD; O'Donnell, D; Rothfield, NF; Csuka, ME. Minocycline Is Not Effective in Systemic Sclerosis: results of an open-label multicenter trial. Arthritis Rheum 2004 Feb;50(2):553-7 PMID: 14872498 02/12/2004.
21. Jaovisidha, K; Csuka, ME; Almagro, U; Soergel, K. Severe Gastrointestinal Involvement In Systemic Sclerosis: Report of five cases and review of the literature. Semin Arthritis Rheum 2005 Feb;34(4):689-702 PMID: 15692963 02/05/2005.
22. Weihrauch, D; Xu, H; Shi, Y; Wang, J; Brien, J; Jones, DW; Kaul, S; Komorowski, RA; Csuka, ME; Oldham, KT; Pritchard, Jr, KA. Effects of D-4F vasodilation, oxidative stress, angiostatin, myocardial inflammation and angiogenic potential in Tight-skin mice. Am J Physiol Heart Circ Physiol 2007 Sep;293(3):H1432-41 PMID: 17496220 Scopus ID: 2-s2.0-34548433520 05/15/2007.
23. Gazi, H; Pope, JE; Clements, P; Medsger, TA; Martin, RW; Merkel, PA; Kahaleh, B; Wollheim, FA; Baron, M; Csuka, ME; Emery, P; Belch, JF; Hayat, S; Lally, EV; Korn, JH; Czirjak, L; Herrick, A;Voskuyl, AE; Bruehlmann, P; Inanc, M; Furst, DE; Black, C; Ellamn, MH; Moreland, L; Rothfield, NF; Myes, M; Mckown, KM; Kreig, T; Siebold, JR. Outcome measurements in scleroderma: results from a delphi exercise. Journal of Rheumatology 2007 Mar;34(3):501-9 PMID: 17299843 02/15/2007.
24. Khanna, D; Clements, PJ; Furst, DE; Korn, JH; Ellman, M; Rothfield, N; Wigley, FM; Moreland, LW; Silver, R; Kim, YH; Steen, VD; Firestein, GS; Kavanaugh, AF; Weisman, M; Mayes, MD; Collier, D; Csuka, ME; Simms, R; Merkel, PA; Medsger, TA Jr; Sanders, ME; Maranian, P; Seibold, Jr. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism 60(4):1102-11, 2009.
25. Chung, L; Shapiro, L; Fiorentino, D; Baron, M; Shanahan, J; Sule, S; Hsu, V; Rothfield, N; Steen, V; Martin, RW; Smith, E; Mayes, M; Simms, R; Pope, J; Kahaleh, B; Csuka, ME; Gruber, B; Collier, D; Sweiss, N; Gilbert, A; Dechow,FJ; Gregory, J; Wigley, FM. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial. Arthritis Rheum 2009 Mar;50(3):870-7 PMID: 19248104 02/28/2009.
26. Khanna, D; Clements, PJ; Furst, DE; Korn, JH; Ellman, M; Rothfield, N; Wigley, FM; Moreland, LW; Silver, R; Kim, YH; Steen, VD; Firestein, GS; Kavanaugh, AF; Weisman, M; Mayes, MD; Collier, D; Csuka, ME; Simms, R; Merkel, PA; Medsger, TA Jr; Sanders, ME; Maranian, P; Seibold, JR. Relaxin Investigators and the Scleroderma Clinical Trials Consortium. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009 Apr;60(4):1102-11 PMID: 19333948 PMICID: PMC3711466 04/01/2009.
27. Xu, H; Zaidi, M; Struve, J; Jones, DW; Krolikowski, JG; Nandedkar, S; Lohr, NL; Gadicherla, A; Pagel, PS; Csuka, ME; Prichard, KA; Weihrauch, D. Abnormal fibrillin-1 expression and chronic oxidative stress mediate endothelial mesenchymal transition in a murine model of systemic sclerosis. American Journal of Physiology-Cell Physiology 2011 Mar;300(3):C550-6 PMID: 21160034 PMCID: PMC3063974 Scopus ID: 2-s2.0-79952158516 12/17/2010.
28. Kushi, J; Csuka, ME. Generalized Morphea after Breast Cancer Radiation Therapy. Case Rep Rheumatol 2011;2011:951948 PMID: 22937449 PMC3420376 01/01/2011.
29. Fransen, J Johnson SR, van den Hoogen, F Baron, M Allanore, Y Carreira, PE Czirjak, L Denton, CP Distler, O Furst, DE Gabrielli, A Inanc, M Kahaleh, B Kowal-Bielecka, O Medsger, TA Mueller-Ladner, U Riemekasten, G Sierakowski, S Valentini, G Veale, D Vonk, MC Walker, U Chung, L Clements, PJ Collier, DH Csuka, ME Jimenez, S Merkel, PA Seibold, JR Silver, R Steen V, Tyndall, A Matucci-Cerinic, M Pope, JE Khanna, D Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. Arthritis Care Res (Hoboken) 2012 Mar;64(3):351-7 PMID: 22052558 PMCID: PMC3288452 11/05/2011.
30. Bae, S Saggar, R Bolster, MB Chung, L Csuka, ME Derk, C Domsic, R Fischer, A Frech, T Goldberg, A Hinchcliff, M Hsu, V Hummers, L Schiopu, E Mayes, MD McLaughlin, V Molitor, J Naz, N Furst, DE Maranian, P Steen, V Khanna, D. Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. Ann Rheum Did 2012 Aug;71(8):1335-42 PMID: 22307943 PMCID: PMC3398226 02/07/2012.
31. Hung, EW Mayes, MD Sharif, R Assassi, S Machicao VI Hosing, C St. Clair, EW Furst DE, Khanna, D Forman, S Mineishi, S Phillips, K Seibold, JR Bredeson, C Csuka, ME
32. Nash, RA Wener, MH Simms, R Ballen, K , Storek, J Goldmuntz, E Welch, B Keyes-Elstein, L Castina, S Crofford, LJ Mcsweeney, P Sullivan, KM. Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trial. Journal of Rheumatology 2013 Apr;40(4):455-60 PMID: 23418384 PMCID: PMC3652008 02/19/2013.
33. Ryan, P Maierle, D, Csuka, ME Thomson, A Szabo. Computer-based intervention to enhance self-management of calcium and vitamin D intake in women. West J Nurs Res 2013 Sep;35(8):986-1010 PMID: 23539320 PMCID: PMC4545626 03/30/2013.
34. Van den Hoogen, F Khanna, D, Fransen, J Johnson, SR Braon, M Tyndall, A Matucci-Cerinic, M Naden, RP Mdsger, TA Carreira, PE Riemekasten, G Clements, PJ Denton, CP Distler, O Allanor, Y Furst, DE Gavrielle, A Mayer, MD van Laar, JM Seibold JR Czirjak, L Steen, VD Inanc, M Kowal-Bielecka, O Mulle-Ladner, U Valentini, G Veale, DJ Vonk, MC Walker, UA Chung, L Collier DH Csuka, ME Fessler, BJ Guiducci, S Herrick, A Hsu, VM Jimenez, S Kahaleh, B Merkel, PA Sierakowski, S Silver, RM Simms, RW Varga, J Pope, JE. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013 Nov;65(11):2737-47 PMID: 24122180 PMCID: PMC3930146 10/15/2013.
35. Chung, L Domsic, RT Lingala, B Alkassab, F Bolster, M Csuka, ME Derk, C Fischer, A Frech, T Furst, DE Gomberg-Maitland, M Hinchcliff, M Hsu, V Hummers, LK Khanna, D Medsger, TA Molitor, JA Preston IR, Schiopu, E Shapiro, L Silver, R Simms, R Varga, J Gordon, JK Steen, VD. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Car Res (Hoboken) 2014 Mar;66(3):489-95 PMID: 23983198 08/29/2013.
36. Hsu VM. Chung L. Hummers LK. Wigley F. Simms R. Bolster M. Silver R. Fischer A. Hinchcliff ME. Varga J. Goldberg AZ. Derk CT. Schiopu E. Khanna D. Shapiro LS. Domsic RT. Medsger T. Mayes MD. Furst D. Csuka ME. Molitor JA. Alkassab F. Steen VD. Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. Semin Arthritis Rheum 2014 Aug;44(1):55-62 PMID: 24709277 04/09/2014.
37. Fischer A, Swigris JJ, Bolster MB, Chung L, Csuka ME, Domsic R, Frech T, Hinchcliff M, Hsu V, Hummers LK, Gomberg-Maitland M, Mathai SC, Simms R, Steen VD. Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters. Clin Exp Rheumatol 2014 Nov-Dec;32(6 Suppl 86):S-109-14 PMID: 25372796 11/06/2014.
38. Shah AA, Schiopu E, Chatterjee S, Csuka ME, Frech T, Goldberg A, Spiera R, Peng SL, McBride RJ, Cleveland JM, Steen V. The Recurrence of Digital Ulcers in Patients with Systemic Sclerosis after Discontinuation of Oral Treprostinil. J Rheumatol. 2016 Sep;43(9):1665-71.
39. Sullivan KM; Goldmuntz EA; Keyes-Elstein L; McSweeney PA; Pinckney A; Welch B; Mayes MD; Nash RA; Crofford LJ; Eggleston B; Castina S; Griffith LM; Goldstein JS; Wallace D; Craciunescu O; Khanna D; Folz RJ; Goldin J; St Clair EW; Seibold JR; Phillips K; Mineishi S; Simms RW; Ballen K; Wener MH; George GE; Heimfeld S; Brasington R; Csuka ME; Bredeson C; Keever-Taylor C; Domsic RT; Kahaleh MB; Medsger T; Furst; SCOT Study Investigators. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med 2018 01 04;378(1):35-47 PMID: 29298160 PMCID: PMC5846574 01/04/2018.
40. Ryan P, Papanek P, Csuka ME, Brown ME, Hopkins S, Lynch S, Scheer V, Schlidt A, Yan K, Simpson P, Hoffman R, Striving to be Strong Team) Background and method of the Striving to be Strong study a RCT testing the efficacy of a m-health self-management intervention. Contemp Clin Trials 2018 08;71:80-87 PMID: 29894865 Scopus ID: 2-s2.0-85048278984 06/13/2018.
41. Hsu VM, Chung L, Hummers LK, Shah A, Simms R, Bolster M, Hant FN, Silver RM, Fischer A, Hinchcliff ME, Varga J, Goldberg AZ, Derk CT, Schiopu E, Khanna D, Shapiro LS, Domsic RT, Medsger T, Mayes MD, Furst D, Csuka ME, Molitor JA, Saketkoo LA, Salazar CR, Steen VD. Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry. J Rheumatol. 2019 Feb;46(2):176-183.
42. Cleland BT, Papanek P, Ingraham BA, Harkins A, Garnier-Villarreal M, Woo D, Csuka ME, V Ng A. Determinants of low bone mineral density in people with multiple sclerosis: Role of physical activity. Mult Scler Relat Disord. 2020 Feb;38:101864.
43. Ryan P, Brown RL, Csuka ME, Papanek P. Efficacy of Osteoporosis Prevention Smartphone App. Nurs Res. 2020;69(1):31-41. PMCID: PMC7105101
44. Francesca Ingegnoli 1, Ariane L Herrick 2, Tommaso Schioppo 1, Francesca Bartoli 1, Nicola Ughi 1, John D Pauling 3, Alberto Sulli 4, Maurizio Cutolo 4, Vanessa Smith 5 6 7, European League against Rheumatism (EULAR) study group on microcirculation in rheumatic diseases and the Scleroderma Clinical Trials Consortium Collaborators, European League against Rheumatism (EULAR) study group on microcirculation in rheumatic diseases and the Scleroderma Clinical Trials Consortium: Mary Ellen Csuka, et. al. Reporting items for capillaroscopy in clinical research on musculoskeletal diseases: a systematic review and international Delphi consensus. Rheumatology (Oxford) 2021 Mar 2;60(3):1410-1418 doi: 10.1093/rheumatology/keaa457.
45. Lymphocyte subset abnormalities in early severe scleroderma favor a Th2phenotype and are not altered by a prior immunosuppressive therapy. Shah A, Storek J, Woolson r, Pinckney A, Keyes-Elstein L, Wallace PK, Sempowski GD, McSweeney P, Mayes MD, Crofford L, Csuka ME, Phillips K, Khanna D, Simms R, Ballen K, LeClerq S, St Clair W, Nixon AB, Nash R, Wener M, Brasington R, Silver R, Griffith LM, Furst DE, Goldmuntz E, Sullivan KM. Rheumatology (Oxford). 2022 Feb 2:keac015. doi: 10.1093/rheumatology/keac015. Online ahead of print. PMID: 35108379
46. Zheng B, Wang M, McKenna K, Shapiro L, Silver R, Csuka ME, van den Hoogen F, Robinson D, Pauling JD, Hummers L, Krieg T, Del Galdo F, Spiera R, Jones N, Khalidi N, Vacca A, de Vries-Bouwstra JK, Gordon J, Baron M. Agreement Between Physician Evaluation and the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis. Arthritis care & research. 74(11):1806-1812, 2022 11. UI: 38662853
47. Keyes-Elstein L, Pinckney A, Goldmuntz E, Welch B, Franks JM, Martyanov V, Wood TA, Crofford L, Mayes M, McSweeney P, Nash R, Georges G, Csuka ME, Simms R, Furst D, Khanna D, Clair EWS, Whitfield ML, Sullivan KM. Clinical and Molecular Findings After Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data. Arthritis Care Res (Hoboken). 2023 Feb;75(2):307-316. doi: 10.1002/acr.24785. Epub 2022 Nov 16. PMID: 34533286; PMCID: PMC8926930.
48. Collaborators RESOLVE-1 Study Group: Arthur Kavanaugh, Daniel E Furst, Suzanne Kafaja, Lorinda Chung, Aryeh Fischer, Virginia Steen, John Varga, Lesley Saketkoo, Laura Hummers, Flavia V Castelino, Robert Simms, Vivek Nagaraja, Jerry Molitor, Nicole M Orzechowski, Vivien M Hsu, Elana J Bernstein, Robert Spiera, Jessica Gordon, Soumya Chatterjee, Bashar Kahaleh, Nora Sandorfi, Robyn T Domsic, Edwin Smith, Zoran Kurepa, Maureen Mayes, Tracy Frech, Mary Ellen Csuka, Susanna Proudman, Vivek Thakkar, Wendy Stevens, Peter Youssef, Murray Baron, David Robinson, Claudia Kedor, Jörg Distler, Stephanie Finzel, Pia Moinzadeh, Ramona König, Christiane Pfeiffer, Norbert Blank, Alexandra Balbir-Gurman, Itzhak Rosner, Yair Levy, Merav Lidar, Eun Bong Lee, Chang Keun Lee, Jae-Bum Jun, Ji Hyeon Ju, V A S H Dalm, Anne A Schouffoer, Jeska Kirsten de Vries-Bouwstra, Dorota Krasowska, Piotr Leszczynsk, Bozena Kowalewska, Ivan Castellvi Barranco, Juan Jose Alegre Sancho, Andrea Rubbert-Roth, Oliver Distler, Francesco Del Galdo, Christopher C Denton, David D'Cruz, Ariane Herrick, Colin Baines, Bridget Griffiths, Karen Douglas Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis Arthritis Rheumatol 2023 Sep;75(9):1608-1618. Doi: 10.1002/art.42510.Epub 2023 June 15.
49. Rosenthal AK, Csuka ME, Halverson P. Daniel J McCarty, MD: A Giant of Rheumatology. Rheum Dis Clin North Am. 2024 Feb;50(1):15-23.
50. Shah A, Storek J, Woolson R, Pinckney A, Keyes-Elstein L, Wallace PK, Sempowski GD, McSweeney P, Mayes MD, Crofford L, Csuka ME, Phillips K, Khanna D, Simms R, Ballen K, LeClercq S, Clair WS, Nixon AB, Nash R, Wener M, Brasington R, Silver R, Griffith LM, Furst DE, Goldmuntz E, Sullivan KM. Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy. Rheumatology (Oxford). 2022 Oct 06;61(10):4155-4162. PMCID: PMC9536786
51. Keyes-Elstein L, Pinckney A, Goldmuntz E, Welch B, Franks JM, Martyanov V, Wood TA, Crofford L, Mayes M, McSweeney P, Nash R, Georges G, Csuka ME, Simms R, Furst D, Khanna D, Clair EWS, Whitfield ML, Sullivan KM. Clinical and Molecular Findings After Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data. Arthritis Care Res (Hoboken). 2023 Feb;75(2):307-316. PMCID: PMC8926930
 
Books, Chapters, and Reviews
1. Csuka, ME; Goodwin, JS. Rheumatoid Arthritis. In Principles of Geriatric Medicine and Gerontology, 2nd Ed., pg. 869-879. Hazzard WR, Andres RB, Bierman EL, Blass JP (eds). New York: McGraw-Hill, 1988.
2. Csuka, ME; McCarty, DJ. Aspirin and the Treatment of Rheumatoid Arthritis. Clinic of Rheumatic Disease 15: 439-454; 1989.
3. Krasnow, AZ; Collier, BD; Csuka, ME; Hellman, RS; Isitman, AT. Nuclear Medicine Evaluation of Amyloidosis. Nuclear Medicine Annual; pp. 123-156; 1992.
4. Csuka, ME. Disabling Rheumatologic Conditions Affecting Women. In Welner's Guide to the Care of Women with Disabilities, pg. 48-68. Welner SL, Haseltine, F (eds). New York: Lippincott, Williams & Wilkins 2004.
5. Daniel J McCarty, MD: A Giant of Rheumatology. Rheum Dis Clin North Am 2024 Feb;50(1):15-23 PubMed ID 37973282 Scopus ID 2-s2.0-085169505673
 
Editorials, Letters To Editor, Other
1. Csuka, ME; McCarty, DJ. Transient Hypothermia after Corticosteroid Treatment of Subacute Cutaneous Lupus Erythematosus. J Rheumatol 1984 Feb;11(1):112-3 PMID: 6699827 02/01/1984.
2. McCarty, D; Csuka, ME. Aspirin in the Treatment of Chronic Inflammatory Arthritis. JAMA 1987 Mar 13;257(10):1331 PMID: 3820440 03/13/1987.
3. McCarty, DJ; Csuka, ME. Polysynovitis associated with acute Epstein-Barr virus infection. J Rheumatol 1998 Oct;25(10):2039-40 PMID: 9779871 10/21/1998.
 
Non-Refereed Journal Publications/Original Papers
1. Gambert, SR; Csuka, ME; Duthie, EH Jr; Tiegs, R. Interpretation of Laboratory Tests in the Elderly. 1.A Clinician's Guide to hepatorenal function tests. Postgrad Med 1982 Sep;72(3):147-52 PMID: 7122336 Scopus ID: 2-s2.0-0020385067 09/01/1982.
2. Csuka, ME. High Dose Immununosuppressive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Treatment of Severe Systemic Sclerosis. Scleroderma Care and Research 3:3-13, 2005.
 
Abstracts
1. Csuka, ME; Black, C; May, G; Porter, J; Branch, R. Rapid Dapsone Hydroxylation in Systemic Sclerosis; A Novel Hypothesis. Arthritis and Rheumatism 30:S99, D43, 1987.
2. Csuka, ME; Valen, PA; Rilling, W; Grist, T; Wortmann, RL. In vivo Assessment of Muscle Energetics in Patients with Primary Fibromyalgia. Arthritis and Rheumatism 32:R33, 1989.
3. Lupoli, S; Csuka, ME; Shapiro, L; Black, C. Cardiac Disease in Systemic Sclerosis (SSC): Non-Invasive Investigtions during Medicum Term Follow-Up. Arthritis and Rheumatism 32:R33, 1989.
4. Black, C; Olsen, N; May, G; Csuka, ME; Tanner, B; Wilkinson, GR; Branch, RA. Scleroderma is Associated With Different Effects on Individual Routes of Drug Metabolism: A Study with Dapsone, Debrisoquine, and Mephenytoin. Arthritis and Rheumatism 32:S94, C22, 1989.
5. Trotter, D; McCarty, DJ; Csuka, ME. Treatment of Dermatomyositis / Polymyositis (DM / PM) with Combination Chemotherapy in Early Disease. Presented at Polymyositis Symposium, San Antonio, Texas, March 21, 1991.
6. Csuka, ME; Branch, RA; Wilkinson, GR; May, G; Lupoli, S; Black, C. Activity of Oxidative Routes of Metabolism of Debrisoquine, Mephenytoin and Dapsone in Vinylchloride-Induced Disease: A Possible Pathogenic Role for Cytochrome P450IID. Presented at the International Conference on Scleroderma and Scleroderma-Like Diseases, Swieradow-Zdroj, Poland, June 1991.
7. Darton, K; Tanner, SB; Watson, HR; Csuka, ME; Black, CM. Long-Term Follow-Up of Iloprost Infusion in Patients with Connective Tissue Disease Using Infra-Red Thermography. Presented at Fifth World Congress for Microcirculation, Louisville, Kentucky, September 1991.
8. Cardenal, A; Masuda, I; Ono, W; Haas, AL; Ryan, LM; Csuka, ME; Trotter, D; McCarty, DJ. Serum nucleoside triphosphate pyrophosphohydrolase (NTPPHASE) activity: Elevated levels in osteoarthritis, calcium phyrophosphate crystal deposition disease and fibromyalgia. Arthritis & Rheumatism 39:S83 #341, 1996.
9. Seibold, JR; Korn, J; Simms, R; Clements, PJ; Moreland, L; Mayes, MD; Merkel, DE; Csuka, ME; Rocco, S; Erikson, M; Hannigan, J; Harkonen, WS; Sanders, ME. Controlled Trial of recombinant human relaxin (rhRlxn) in diffuse scleroderma (DS). Arthritis and Rheumatism 40:S123 #557, 1997.
10. Csuka, ME; Taylor, ML; Tapal, M; Madigan, GJ; Gardner, J; Tonellato, P. Randomized double blind placebo controlled trial comparing melatonin to placebo in the treatment of fibromyalgia. Arthritis & Rheumatism 41:S258 #1356, 1998.
11. Mayes, MD; O’Donnell, D; Csuka, ME; Rothfield, NF. Multicenter, open-label trial of minocycline in early diffuse SSc. Arthritis & Rheumatism 46:S357 #914, 2002.
12. Chung, L, Baron; M, Collier, D; Csuka, ME; Fiorentino, D; Gruber, B; Hsu, V; Kahaleh, B; Martin, R; Mayes, M; Pope, J; Rothfield, N; Shanahan, J; Shapiro, L; Simms, R; Smith, E; Steen, V; Sule, S; Sweiss, N; Matthews, E; Gilbert, A; Dechow, J; Wigley, F. A multi-center, blinded, randomized, placebo-controlled, “in-life” study of MQX-503, a topical gel formulation of nitroglycerin, in subject with Raynaud’s phenomenon. 2007
13. Schiopu, E; Hsu ,VM; Hummers, LK; Shapiro, LS; Mayes, MD; Csuka, ME; Derk, CT; Chung, LS; Varga, J; Furst, DE; Silver, RM; Wigley, FM; Seibold, JR; Steen, VD. Pulmonary Hypertension (PH)-Assessment and Recognition of Outcomes in Scleroderma (Systemic Sclerosis, SSc): PHAROS. Arthritis & Rheumatism 56:S489 #1208, 2007.
14. Fischer, A; Impens, A; Hsu, V; Shapiro, L; Mayes, M; Hummers, L; Csuka, ME; Chun, L; Hinchcliff, M; Varga, J; Derk, C;Seibold, J; Steen. “PHAROS” Pulmonary Hypertension (PH) Assessment and Recognition of Outcomes in Systemic Sclerosis (SSc): Pre-Pulmonary Arterial Hypertension (PAH) Preliminary Outcomes. Arthritis & Rheumatism 58:S377 #566, 2008.
15. Mayes, MD; Keyes-Elstein, L; Crofford LJ; Csuka, ME; Furst, DE; Goldmuntz, E; McSweeney P; Nash, R; Wallace, D; Sullivan. Gastric Antral Vascular Ectasia (GABE) in Early Diffuse SSc: Report from the SCOT Trial. Arthritis & Rheumatism 58:S378 #571, 2008.
16. Hsu, V; Shapiro, L; Fiorentino, D; Rothfield, N; Steen, V; Martin, R; Smith, E; Sule, S; Csuka, ME; Mayes, M; Kahaleh, B; Gruber, B; Simms, R; Sweiss, N; Dechow, FJ; Gregory, JK; Wigley, FM. Phase III Open-Label Study of Topical Nitroglycerin, MQX-503, in the Treatment and Prevention of Raynaud’s Phenomenon. Arthritis & Rheumatism 58:S820 #1773, 2008.
17. Khawari, M; Jacob, S; Soto, FJ; Presberg, K; Csuka, ME. Prevalence of Obstructive Sleep Apnea in Patients with Connective Tissue Disease and Pulmonary Hypertension. Arthritis & Rheumatism 58:S829 #1798, 2008.
18. Hinchcliff, ME; Hsu, V; Bolster, M; Hummers, L; Seibold, J; Csuka, ME; Chung, L; Shapiro, L; Derk, C; Fischer, A; Wigley, F; Steen, V. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): Patients with Pulmonary Hypertension. Arthritis & Rheumatism 58: S948 #2124, 2008.
19. Fischer, A; Mathai, S; Bolster, MB, Chung, L; Csuka, ME; Domsic, R; Frech, T; Hinchliff, M; Hsu, V; Hummers, L; Kolfenbach, J; Gomberg-Maitland, M; Manu, A; Simms, R; Steen, V. Pulmonary Hypertension and Interstitial Lung Disease within Pharos: Impact of Extent of Fibrosis and Pulmonary Physiology On Cardiac Hemodynamic Parameters. Rheumatology/ILD Program, National Jewish Health, Denver, CO, Medicine, Johns Hopkins University, Baltimore, MD, Medicine, Medical University of South Carolina, Charleston, SC, Rheumatology, Stanford University Medical Center, Palo Alto, CA, Rheumatology, Medical College of Wisconsin, Milwaukee, WI, Medicine, Rheumatology, University of Pittsburgh, Pittsburgh, PA, Internal Medicine Division of Rheumatology, University of Utah School of Medicine, SLC, UT, Division of Rheumatology, Northwestern University Medical School, Chicago, IL, Rheumatology, RWJ Medical School Scleroderma Program, New Brunswick, NJ, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, University of Chicago, Chicago, Rheumatology Georgetown University Medical Center, District of Columbia, Rheumatology, Boston University School of Medicine, Boston, MA, Department of Rheumatology, Georgetown University Medical Center, Washington DC. 2012 ACR/ARHP Annual Meeting.
20. Van de Hoogen, F; Khanna, D; Fransen, J; Johnson, SR; Baron, M; Tyndall, A; Matucci-Cerinic, M; Naden, RP; Medsger, TR Jr; Carreira, PE; Riemekasten, G; Clements, PJ; Denton, CP; Distler, O; Allanore, Y; Furst, DE; Gabrielli, A; Mayes, MD; van Laar, JM; Seibold, JR; Czirjak, L; Steen, VD; Inanc, M; Kowal-Bielecka O; Mueller-Ladner, U; Valentini, G; Veale, DJ; Vonk, MC; Walker, UA; Chung, L; Collier, DH; Csuka, ME; Fessler, BJ; Guiducci, S; Herrick, A; Hsu, VM; Jimenez, S; Kahaleh, B; Merkel, PA; Sierakowski, S; Silver, RM; Simms, RW; Varga, J; Pope, JE. 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013 Nov;65(11):2737-47. Doi: 10.1002/art.38098. Epub 2013 Oct 3.
21. Ami A., Shah; Schiopu, E; Chatterjee, S; Csuka, ME; Frech, T; Goldberg, A; Spiera, R; Peng, S; Steen, V. A Retrospective Look at the Recurrence of Digital Ulcers in Patients with Scleroderma after Discontinuation of Oral Treprostinil. Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, Rheumatology, University of Michigan, Ann Arbor, MI, Rheumatic and Immunologic Ds, Cleveland Clinic, Cleveland, OH, Rheumatology, Medical College of Wisconsin, Milwaukee, WI, Division of Rheumatology, University of Utah, Salt Lake City, UT, Division of Rheumatology, North Shore-LIJ Health System, Great Neck, NY, Rheumatology, Hospital for Special Surgery, New York, NY, Benaroya Research Institute/Virginia Mason, Seattle, WA, Department of Rheumatology, Georgetown University Medical Center, Washington, DC. 2014 ACR/ARHP Annual Meeting.
22. Shah, A; Chatterjee, S; Csuka, ME; Frech, T; Goldberg, A; Spiera, R; Peng, S; Steen, V. A Retrospective Look at the Recurrence of Digital Ulcers in Patients with Scleroderma after Discontinuation of Oral Treprostinil. American College of Rheumatology Annual Conference – Boston Convention and Exhibition Center – presentation number 1927; Nov 17, 2014
23. Papanek, Paula; Marquette University; Speltz, Jenna; Csuka, ME; Ryan, Polly. High Prevalence of Low BMD in Middle Aged Healthy Women. Journal of Clinical Densitometry: Assessment & Management of Musculoskeletal Health. Volume 18, 2015
24. Shervin, A; Mayes, MD; Pedroza, C; Chang, JT; Furst, DE; Crofford, LJ, Nash, R; McSweeney, P; Csuka, ME; Goldmuntz, E; Keyes-Elstein, L; Wallace, P; Sullivan, K. Immunoablation Followed By Autologous Stem Cell Transplantation in Systemic Sclerosis Patients Decreases Significantly the Interferon Signature. Rheumatology, University of Texas Medical School at Houston, Houston, TX, University of Texas Medical School at Houston, TX, Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, Medicine, Vanderbilt University, Nashville, TN, Colorado Blood Cancer Institute, Denver, CO, Rheumatology, Medical College of Wisconsin, Milwaukee, WI, NIAID, National Institutes of Health, Bethesda, MD, Rho Federal Systems, Inc., Chapel Hill, NC, Roswell Park, Buffalo, NY, Duke University, Durham, NC. 2015 ACR/ARHP Annual Meeting.
25. Shah AA; Schiopu E; Chatterjee S.; Csuka ME; Frech T; Goldberg A; Spiera R; Peng SL; McBride RJ; Cleveland JM; Steen V. The Recurrence of Digital Ulcers in Patients with Systemic Sclerosis after Discontinuation of Oral Treprostinil. J Rheumatol 2016 09:43(9):1885-71 PMID: 27307535 06/17/2016.
26. Chung L; Fairchild RM; Furst DE; Li S; Alkassab F; Bolster MB; Csuka ME; Derk CT; Domsic RT; Fischer A; Frech T; Gomberg-Maitland M; Gordon JK; Hinchcliff M; Hsu V; Hummers LK; Khanna D; Medsger TA; Molitor JA; Preston IR; Schiopu E; Shapiro L; Hant F; Silver R; Simms R; Varga J; Steen VD; Zamanian RT. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. Clin Exp Rheumatol 2017 Sep-Oct;35 Suppl 106(4): 106-113 PMID: 27908301 12/03/2016
27. Ding, Y; Yeturi, S; Gohr, C; Csuka, ME; Rosenthal, A. Low Nucleoside Triphosphate Pyrophosphohydrolase Activity Contributes to Pathologic Mineralization in Systemic Sclerosis. Medicine, Medical College of Wisconsin, Milwaukee, WI, Medicine, Clement J. Zablocki VA Medical Center, Milwaukee, WI. 2016 ACR/ARHP Annual Meeting.
28. Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM, SENSCIS Trial Investigators. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019 Jun 27;380(26):2518-2528
29. American College of Rheumatology (ACR) Convergence November 2023 – San Diego, CA - Chelation Therapy in the Management of Calcinosis Associated with Systemic Sclerosis Alison Fernandes, Ashraf El-Meanawy and ME Csuka, Medical College of Wisconsin, Milwaukee, WI